Overview

A Phase II, Muti-Center Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A

Status:
Not yet recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

Primary objective: To assess the pharmacokinetics, Safety and immunogenicity of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A(FRSW117) Secondary objectives: To assess Preliminary efficacy of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection With Severe Hemophilia A.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu Gensciences lnc.

Treatments:

Factor VIII